Forbes.com - BIOMARIN PHARMACEUTICAL (4, BMRN) is the classic biotech, convertible-debt-laden and intensely unprofitable. But Quinterol Mallette, portfolio manager at Mallette Capital Management, argues that Aldurazyme, BioMarin's treatment for a children's enzyme-deficiency disease, is about to take off. What's more, BioMarin acquired Ascent Pediatrics, a profitable biotech with its own pediatrics sales force.